

# Finn Sellebjerg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3033984/publications.pdf>

Version: 2024-02-01

113  
papers

6,593  
citations

147566

31  
h-index

69108

77  
g-index

123  
all docs

123  
docs citations

123  
times ranked

11093  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study. <i>European Journal of Neurology</i> , 2022, 29, 496-504.	1.7	8
2	Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal. <i>Multiple Sclerosis Journal</i> , 2022, 28, 16-28.	1.4	5
3	The prognostic value of neurofilament light chain in serum. <i>Lancet Neurology</i> , The, 2022, 21, 207-208.	4.9	3
4	Pregnancy in women with MS: Impact on long-term disability accrual in a nationwide Danish Cohort. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1239-1247.	1.4	7
5	Extended dosing of monoclonal antibodies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2001-2009.	1.4	16
6	Linking lesions in sensorimotor cortex to contralateral hand function in multiple sclerosis: a 7-T MRI study. <i>Brain</i> , 2022, 145, 3522-3535.	3.7	6
7	Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	17
8	Neurofilament Light in Cerebrospinal Fluid is Associated With Disease Staging in European Lyme Neuroborreliosis. <i>Journal of Central Nervous System Disease</i> , 2022, 14, 117957352210981.	0.7	2
9	Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	15
10	Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	11
11	Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 188-197.	1.4	8
12	Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 556-562.	0.9	7
13	Cladribine inhibits secretion of pro-inflammatory cytokines and phagocytosis in human monocyte-derived M1 macrophages in-vitro. <i>International Immunopharmacology</i> , 2021, 91, 107270.	1.7	8
14	Pregnancy-Related and Perinatal Outcomes in Women With Multiple Sclerosis. <i>Neurology: Clinical Practice</i> , 2021, 11, 280-290.	0.8	11
15	CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes. <i>Scientific Reports</i> , 2021, 11, 4132.	1.6	10
16	Neutrophil-to-lymphocyte ratio and CRP as biomarkers in multiple sclerosis: A systematic review. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 577-586.	1.0	27
17	Targeting B cells in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2021, 34, 295-302.	1.8	5
18	Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2254-2266.	1.4	11

#	ARTICLE	IF	CITATIONS
19	Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry. PLoS ONE, 2021, 16, e0250820.	1.1	12
20	Serum Short-Chain Fatty Acids and Associations With Inflammation in Newly Diagnosed Patients With Multiple Sclerosis and Healthy Controls. Frontiers in Immunology, 2021, 12, 661493.	2.2	43
21	Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS. Multiple Sclerosis and Related Disorders, 2021, 50, 102813.	0.9	7
22	Population-based head-to-head comparison of the clinical characteristics and epidemiology of AQP4 antibody-positive NMOSD between two European countries. Multiple Sclerosis and Related Disorders, 2021, 51, 102879.	0.9	3
23	Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Multiple Sclerosis and Related Disorders, 2021, 52, 102988.	0.9	24
24	Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 52, 102987.	0.9	11
25	IL2RA Methylation and Gene Expression in Relation to the Multiple Sclerosis-Associated Gene Variant rs2104286 and Soluble IL-2R $\beta$ in CD8 <sup>+</sup> T Cells. Frontiers in Immunology, 2021, 12, 676141.	2.2	6
26	Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 1197.	4.5	90
27	Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1065.	3.1	1
28	The effectiveness of natalizumab vs fingolimod—A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	0.9	8
29	Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	15
30	The Effect of Cannabis-Based Medicine on Neuropathic Pain and Spasticity in Patients with Multiple Sclerosis and Spinal Cord Injury: Study Protocol of a National Multicenter Double-Blinded, Placebo-Controlled Trial. Brain Sciences, 2021, 11, 1212.	1.1	7
31	Biomarkers of systemic inflammation, soluble IL-2R $\beta$ and the multiple sclerosis-associated IL2RA SNP rs2104286 in healthy subjects and multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 54, 103140.	0.9	5
32	Assessment of commonly used methods to determine myelin-reactivity of T cells in multiple sclerosis. Clinical Immunology, 2021, 230, 108817.	1.4	4
33	Imaging cortical multiple sclerosis lesions with ultra-high field MRI. Neurolmage: Clinical, 2021, 32, 102847.	1.4	8
34	Smoking, cardiovascular risk factors and LRP2 gene variation: Associations with disease severity, cognitive function and brain structure in primary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103296.	0.9	4
35	Application of definitions for conversion to secondary progressive MS in a Danish nationwide population. Multiple Sclerosis and Related Disorders, 2021, 56, 103319.	0.9	6
36	Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 37, 101451.	0.9	18

#	ARTICLE	IF	CITATIONS
37	Brief international cognitive assessment for multiple sclerosis (BICAMS): A danish validation study of sensitivity in early stages of MS. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101458.	0.9	9
38	Serum neurofilament light chain in healthy elderly and in patients with age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2020, 98, e393-e394.	0.6	5
39	Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon- $\beta$ . <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101894.	0.9	1
40	MAIT cell subtypes in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2020, 339, 577117.	1.1	12
41	Motor fatigue is associated with asymmetric connectivity properties of the corticospinal tract in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2020, 28, 102393.	1.4	5
42	Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102391.	0.9	11
43	Serum neurofilament light as a biomarker in progressive multiple sclerosis. <i>Neurology</i> , 2020, 95, 436-444.	1.5	100
44	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020, 143, 2637-2652.	3.7	56
45	Disentangling white-matter damage from physiological fibre orientation dispersion in multiple sclerosis. <i>Brain Communications</i> , 2020, 2, fcaa077.	1.5	55
46	Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS. <i>BMC Medicine</i> , 2020, 18, 298.	2.3	11
47	Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 566-572.	0.5	36
48	Initial high-efficacy disease-modifying therapy in multiple sclerosis. <i>Neurology</i> , 2020, 95, e1041-e1051.	1.5	83
49	Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. <i>CNS Drugs</i> , 2020, 34, 269-280.	2.7	49
50	Pregnancy-Induced Changes in microRNA Expression in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 552101.	2.2	12
51	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	3.9	31
52	Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1298-1305.	1.4	24
53	Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1289-1297.	1.4	18
54	CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage. <i>Multiple Sclerosis Journal</i> , 2019, 25, 937-946.	1.4	32

#	ARTICLE	IF	CITATIONS
55	Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1572-1579.	1.4	14
56	Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1444-1451.	1.4	47
57	Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls. <i>Cells</i> , 2019, 8, 634.	1.8	22
58	Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008-2018: A nationwide, population-based cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 162-167.	0.9	35
59	Diagnostic Value of Oligoclonal Bands in Children: A Nationwide Population-Based Cohort Study. <i>Pediatric Neurology</i> , 2019, 97, 56-63.	1.0	11
60	Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation. <i>Journal of Neuroimmunology</i> , 2019, 330, 90-95.	1.1	6
61	Comparative effectiveness of teriflunomide and dimethyl fumarate. <i>Neurology</i> , 2019, 92, e1811-e1820.	1.5	36
62	IL-6, IL-12, and IL-23 STAT-Pathway Genetic Risk and Responsiveness of Lymphocytes in Patients with Multiple Sclerosis. <i>Cells</i> , 2019, 8, 285.	1.8	18
63	Pulsed immune reconstitution therapy in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641983691.	1.5	54
64	Author response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2019, 93, 723-723.	1.5	0
65	Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. <i>Brain</i> , 2019, 142, 120-132.	3.7	81
66	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019, 326, 19-27.	1.1	22
67	Structural and cognitive correlates of fatigue in progressive multiple sclerosis. <i>Neurological Research</i> , 2019, 41, 168-176.	0.6	14
68	GPR15+ T cells are Th17 like, increased in smokers and associated with multiple sclerosis. <i>Journal of Autoimmunity</i> , 2019, 97, 114-121.	3.0	30
69	Functional neuroimaging of recovery from motor conversion disorder: A case report. <i>NeuroImage</i> , 2019, 190, 269-274.	2.1	9
70	Prediction of natalizumab anti-drug antibodies persistency. <i>Multiple Sclerosis Journal</i> , 2019, 25, 392-398.	1.4	10
71	Smoking affects the interferon beta treatment response in multiple sclerosis. <i>Neurology</i> , 2018, 90, e593-e600.	1.5	38
72	Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2018, 91, e2265-e2275.	1.5	84

#	ARTICLE	IF	CITATIONS
73	B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LT $\alpha$ and TGF $\beta$ 1 response. <i>Journal of Neuroimmunology</i> , 2018, 324, 157-164.	1.1	18
74	Clinical utility of anti-MOG antibody testing in a Danish cohort. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 61-67.	0.9	10
75	Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 175-183.	0.9	17
76	Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes. <i>PLoS ONE</i> , 2018, 13, e0202530.	1.1	28
77	Inflammatory markers of CHMP2B-mediated frontotemporal dementia. <i>Journal of Neuroimmunology</i> , 2018, 324, 136-142.	1.1	10
78	A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. <i>Multiple Sclerosis Journal</i> , 2017, 23, 234-241.	1.4	38
79	Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 25-27.	0.9	13
80	Smoking reduces circulating CD26hiCD161hi MAIT cells in healthy individuals and patients with multiple sclerosis. <i>Journal of Leukocyte Biology</i> , 2017, 101, 1211-1220.	1.5	17
81	Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis. <i>Cytokine</i> , 2017, 93, 15-25.	1.4	12
82	Defining active progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1727-1735.	1.4	34
83	Characterization of na $\alpha$ ve, memory and effector T cells in progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017, 310, 17-25.	1.1	20
84	Systemic frequencies of T helper 1 and T helper 17 cells in patients with age-related macular degeneration: A case-control study. <i>Scientific Reports</i> , 2017, 7, 605.	1.6	29
85	The interaction between smoking and HLA genes in multiple sclerosis: replication and refinement. <i>European Journal of Epidemiology</i> , 2017, 32, 909-919.	2.5	45
86	High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. <i>Multiple Sclerosis Journal</i> , 2017, 23, 675-685.	1.4	38
87	Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e287.	3.1	53
88	Neurofilament in CSF – A biomarker of disease activity and long-term prognosis in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1112-1113.	1.4	15
89	Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 169-173.	0.9	68
90	Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 912-914.	0.9	8

#	ARTICLE	IF	CITATIONS
91	Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e191.	3.1	69
92	Human pegivirus detected in a patient with severe encephalitis using a metagenomic pan-virus array. <i>Journal of Clinical Virology</i> , 2016, 77, 5-8.	1.6	17
93	Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 31-43.	1.5	29
94	Association between age at onset of multiple sclerosis and vitamin D level-related factors. <i>Neurology</i> , 2016, 86, 88-93.	1.5	28
95	Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 926-934.	1.4	23
96	Myelin Basic Protein-Induced Production of Tumor Necrosis Factor- $\alpha$ and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2016, 11, e0146971.	1.1	8
97	Endogenous Interferon- $\beta$ -Inducible Gene Expression and Interferon- $\beta$ -Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis. <i>PLoS ONE</i> , 2015, 10, e0118830.	1.1	18
98	Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1414-1422.	1.4	18
99	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015, 138, 632-643.	3.7	54
100	A clinically useful genetic variant in multiple sclerosis?. <i>Nature Reviews Neurology</i> , 2015, 11, 371-372.	4.9	1
101	Natalizumab in progressive MS. <i>Neurology</i> , 2014, 82, 1499-1507.	1.5	110
102	FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. <i>Nature Medicine</i> , 2014, 20, 272-282.	15.2	141
103	Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general. <i>Journal of Neuroimmunology</i> , 2014, 274, 174-179.	1.1	7
104	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013, 45, 1353-1360.	9.4	1,213
105	Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study). <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 141-146.	0.9	6
106	CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 877-884.	1.4	75
107	Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression. <i>PLoS ONE</i> , 2013, 8, e57820.	1.1	213
108	Relationship between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis. <i>PLoS ONE</i> , 2013, 8, e77163.	1.1	55

#	ARTICLE	IF	CITATIONS
109	Endogenous and Recombinant Type I Interferons and Disease Activity in Multiple Sclerosis. PLoS ONE, 2012, 7, e35927.	1.1	14
110	Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis. PLoS ONE, 2012, 7, e47578.	1.1	59
111	Interleukin-2 effect on T cell activation revealed by daclizumab treatment. Multiple Sclerosis and Related Disorders, 2012, 1, 8.	0.9	0
112	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	13.7	2,400
113	Methylprednisolone treatment, immune activation, and intrathecal inflammation in multiple sclerosis. Danish Medical Bulletin, 2004, 51, 167-83.	0.3	0